Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 78 USD 0.46%
Market Cap: 8.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CORT Price Targets Summary
Corcept Therapeutics Inc

Wall Street analysts forecast CORT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CORT is 142.29 USD with a low forecast of 132.31 USD and a high forecast of 157.5 USD.

CORT Lowest Forecast
Wall Street Target
132.31 USD
70% Upside
CORT Average Forecast
Wall Street Target
142.29 USD
82% Upside
CORT Highest Forecast
Wall Street Target
157.5 USD
102% Upside
Lowest
Price Target
132.31 USD
70% Upside
Average
Price Target
142.29 USD
82% Upside
Highest
Price Target
157.5 USD
102% Upside
Corcept Therapeutics Inc Competitors:
Price Targets
G
512
Grand Pharmaceutical Group Ltd
21% Downside
VENUSREM
Venus Remedies Ltd
6% Downside
GS71
GSK plc
13% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
8% Upside
G
512
Grand Pharmaceutical Group Ltd
21% Downside
VENUSREM
Venus Remedies Ltd
6% Downside
GS71
GSK plc
13% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
8% Upside
000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
29% Upside
C
6919
Caliway Biopharmaceuticals Co Ltd
21% Upside
INVA
Innoviva Inc
186% Upside

Revenue
Forecast

Revenue Estimate
Corcept Therapeutics Inc

The compound annual growth rate of Corcept Therapeutics Inc's revenue for the next 3 years is 34%.

N/A
Past Growth
34%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Corcept Therapeutics Inc

The compound annual growth rate of Corcept Therapeutics Inc's operating income for the next 3 years is 92%.

N/A
Past Growth
92%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Corcept Therapeutics Inc

The compound annual growth rate of Corcept Therapeutics Inc's net income for the next 3 years is 66%.

N/A
Past Growth
66%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

See Also

Summary
CORT intrinsic value, competitors valuation, and company profile.
DCF Valuation
CORT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CORT stock valuation using valuation multiples.
Wall Street Estimates
CORT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CORT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CORT's stock price target?
Price Target
142.29 USD

According to Wall Street analysts, the average 1-year price target for CORT is 142.29 USD with a low forecast of 132.31 USD and a high forecast of 157.5 USD.

What is Corcept Therapeutics Inc's Revenue forecast?
Projected CAGR
34%

The compound annual growth rate of Corcept Therapeutics Inc's revenue for the next 3 years is 34%.

What is Corcept Therapeutics Inc's Operating Income forecast?
Projected CAGR
92%

The compound annual growth rate of Corcept Therapeutics Inc's operating income for the next 3 years is 92%.

What is Corcept Therapeutics Inc's Net Income forecast?
Projected CAGR
66%

The compound annual growth rate of Corcept Therapeutics Inc's net income for the next 3 years is 66%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.